hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 10:29:05 - browse：57193

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare Advantage coverage denials need scrutiny, senators say

WSS

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Obesity now affects over 1 billion people worldwide, study finds

An inside look at PIPEs, biotech's buzzy new financing tool

Fauci's latest grilling in Congress: 9 hours, behind closed doors

entertainment

hotspot

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Male doctors called my cancer incurable. A female doctor showed it wasn't

The cancer drug shortage isn’t new — and neither are the solutions

Obesity now affects over 1 billion people worldwide, study finds

Trump demands the U.S. pay no more for drugs than other countries … again

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Peter Hotez and the public health issue of online harassment

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Affirmative action in medical school literally saved lives

AstraZeneca loses challenge to Medicare drug price negotiation

knowledge

A preacher's new calling: Diversifying neuroscience research

RSV vaccines may be linked to small increased risk of developing GBS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

An inside look at PIPEs, biotech's buzzy new financing tool

How to address the problem of discarded donor organs

Wikipedia

leisure time

hotspot

focus